GlassScriptPhysician profile
Arnold Onana
NPI 1255916730
$2,681.96
in general payments reported to CMS, 2019-2025
23 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,074 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,582 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,581.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $349.99 | 2024-2025 | Jakafi, Jakafi |
| Merck Sharp & Dohme LLC | $319.91 | 2024-2025 | Zerbaxa, Prevymis, Recarbrio |
| Daiichi Sankyo INC. | $277.01 | 2024-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $271.94 | 2024-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $249.12 | 2024 | Fruzaqla |
| Syndax Pharmaceuticals, INC. | $169.04 | 2025 | Revuforj |
| Astrazeneca Pharmaceuticals LP | $152.89 | 2024-2025 | Calquence, Enhertu |
| Regeneron Healthcare Solutions, INC. | $121.40 | 2025 | Libtayo |
| Genzyme Corporation | $117.00 | 2024 | |
| Exelixis INC. | $104.52 | 2025 | Cabometyx |
| Pfizer INC. | $85.22 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.12 | 2024-2025 | Vitrakvi, Stivarga, Nubeqa |
| E.R. Squibb & Sons, L.L.C. | $69.16 | 2025 | Opdivo |
| Novocure INC. | $57.46 | 2025 | Optune Lua (Novottf-200t) |
| Sobi, INC | $46.50 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $45.69 | 2025 | Fetroja |
| Janssen Research & Development, LLC | $40.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $36.73 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $27.62 | 2025 | Orgovyx |
| Glaxosmithkline, LLC. | $20.43 | 2025 | Blenrep, Ojjaara |
| Celgene Corporation | $18.67 | 2025 | Reblozyl |
| Azurity Pharmaceuticals, INC. | $17.59 | 2024 | Vivimusta |
| Abbvie INC. | $13.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Onana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.